Association between oxidative stress markers and lung function parameters in stable chronic obstructive pulmonary disease patients

Inflammation plays a role in the pathogenesis of COPD by interfering with the protease/antiprotease and oxidant/antioxidant balance. There is no adequate data about the relationship between oxidative stress biomarkers and FEV1 values in stable COPD patients. Prospective cohort study, designed in tertiary care chest disease hospitals’ outpatient clinic. COPD patients were approved informed consent were included in the study. The total antioxidant status (TAS,), total oxidant status (TOS), total thiol (TT), native thiol (NT), IL1 IL6, and TNFα levels were measured. The mean age of 33 COPD patients who joined the study was 61±9,32 years, while their average body mass index (BMI) was 27±4,31 kg/m2. There was no statistically significant difference between the groups in terms of age, gender, weight, smoking status and comorbidities. According to the results of the analysis, there was a statistically significant difference in TOS, TAS, oxidative stress index (OSI), TT, NT, DIS, IL-1β, IL-6, and TNFα between the control and COPD patient groups (p

PDF

___

1. GOLD 2022 Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022; (Available from: http://goldcopd.org).
2. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease. NHLBI/WHO Workshop Report; 2009.
3. Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Diagnosis and Treatment Guideline. Turkish Thora J. 2010;1:5-24.
4. Gülbay BE, Acican T. Pathogenesis and inflammation. In: Saryal S, Acıcan T ed.: Chronic Obstructive Pulmonary Disease in the light of up-to-date information. Ankara, Sci Med Publishing House.2003;5:21-33.
5. Halliwell B, Gutteridge JM. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet (London,England).1984;1:1396–97.
6. Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47:326–32.
7. Suresh Garudadri and Prescott G. Woodruff, Targeting Chronic Obstructive Pulmonary Disease phenotypes, endotypes, and biomarkers. Ann Am Thorac Soc. 2018;15:234–38.
8. Peter J. Barnes et al. Inflammatory endotypes in COPD. Allergy. 2019;00:1–8.
9. Stockley RA, Halpin DMG, Celli BR, et al. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. Am J Respir Crit Care Med. 2019;199:1195-204.
10. Barnes, PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544.
11. T. Schaberg, U. Klein, M. Rau, et al.Subpopulations of alveolar macrophages in smokers and nonsmokers: relation to the expression of CD11/CD18 molecules and superoxide anion production. Am. J. Respir. Crit. Care Med.1995;151:1551–58.
12. A. Noguera, S. Batle, C. Miralles, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease.Thorax. 2001;56:432–37. 13. Kirkham, P.A. and P.J. Barnes. Oxidative stress in COPD.Chest. 2013;144:266-73.
14. Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, et al.Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med.2011;105:31–37.
15. Ekin S, Arısoy A, Gunbatar H, et al. The relationships among the levels of oxidative and antioxidative parameters, FEV1 and prolidase activity in COPD. Redox Rep. 2017;22:74–77.
16. Rahman I, Swarska E, Henry M, et al. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?. Thorax. 2000;55:189–93.
17. Tavilani H, Nadi E, Karimi J, et al. Oxidative stress in COPD patients, smokers, and non-smokers. Respir Care. 2012;57:2090–94.